Moderna CEO Hints At Possible 3-in-1 COVID-19/Flu/RSV Vaccine by Fall

January 18, 2022

Moderna is poised to commercialize its COVID-19 and influenza combination vaccine by the fall of 2023, with some potential for the same drug to also be viable against the respiratory syncytial virus (RSV). 

Speaking at the World Economic Forum today, Moderna chief executive Stéphane Bancel hopes to develop a single annual booster dose to eliminate the need for people to get two to three jabs every time the winter season nears. Bancel did not give any details on the timeline of the vaccine’s release other than predicting that they might do so next year. 

The COVID-19 booster shot is currently being evaluated in several Phase III studies, while its efficacy and safety as a treatment for flu is still being developed and could progress to Phase III trials in the following months. In September last year, Moderna had also hinted at the possibility of using the same shot for RSV and other similar respiratory diseases.

Read more at BioSpace.

Immunize Colorado